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Altered biodistribution of an antibody-enzyme conjugate modified with
polyethylene glycol
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Summary Polyethyene glycol modification of the antibody-enzyme conjugate, F(ab')2-A5B7-CPG2, extends
its duration in the circulation of nude mice bearing human colonic cancer xenografts (LS174T). Increased
concentration ofmodified conjugate is achieved in the tumour, but residual non-specific enzyme concentrations
in normal tissue and blood demonstrate the fundamental requirement to remove or inactivate non-specifically
held enzyme in this system.
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Antibody-directed enzyme prodrug therapy (ADEPT) holds
promise for more selective delivery of cytotoxic drugs to
tumours in vivo than can be expected from direct parenteral
administration of the active drugs (Bagshawe et al., 1994).
Critical factors for success are the differential concentration of
enzyme at the tumour, rapid removal of unwanted enzyme
from circulation and normal tissues to allow early adminis-
tration and increased dose of the prodrug, and abrogation of
the immunogenicity of the xenogenic proteins. Modifying
proteins with polyethylene glycol (PEG) have been reported to
prolong their circulatory half-lives in vivo (Chen et al., 1981;
Katre et al., 1987; Berger and Pizzo, 1988) and lessen their
immunogenicity (Abuchowski et al., 1977; Nucci et al., 1991).
It is therefore of interest to determine whether this
modification improves or reduces selective retention of the
antibody-enzyme conjugate in a xenograft model.
In this study we report the linkage of PEG (5000 Da) to
a conjugate comprising carboxypeptidase G2 and the F(ab')2
fragment of an anti-CEA monoclonal antibody (A5B7) and
describe the altered distributions encountered in vivo. The
localisation of F(ab')2-A5B7-CPG2 in nude mice bearing
human colonic cancer xenografts has been well characterised
(Sharma et al., 1991), making it a suitable model for
studying the effects of modification with PEG. In addition,
Sharma et al. (1994) have demonstrated that administration
of galactosylated anti-carboxypeptidase monoclonal antibody
(SB43gal) accelerates the clearance of F(ab')2-A5B7-CPG2
from the blood of nude mice, resulting in increased
tumour- organ ratios without affecting conjugate localisa-
tion at the tumour. As a recent paper (Pedley et al., 1994)
has compared in detail the distribution of pegylated
antibody and antibody fragments in LS174T colonic cancer
xenograft models in the context of radiolabelled antibody
therapy, we concentrate in this report on the effect of
pegylation on the requisite targeting of the enzyme to
tumours and the effect of SB43gal on the biodistribution of
the pegylated conjugate.
Materials and methods
Covalent attachment of PEG to F(ab')2-A5B7-CPG2
F(ab')2-A5B7-CPG2, prepared as reported (Melton et al.,
1993), was kindly provided by Dr RG Melton, Division of
Biotechnology, Centre for Applied Microbiology and
Research, Porton Down, Salisbury, UK. An aliquot of
120 mg of methoxypolyethylene glycol p-nitrophenyl carbo-
nate (Sigma), was added to 10.5 mg of F(ab')2-A5B7-CPG2 in
3.2 ml of0.2 M sodium phosphate buffer pH 7.2 (Veronese et
al., 1985). After 1 h at room temperature unreacted PEG was
removed by five successive ultrafiltration steps in an
ultrafiltration cell (Amicon), using an XM-50 membrane.
Each filtration was accomplished using 0.1 M sodium
phosphate buffer, pH 7.2, as the dialysing solution.
Pegylated protein was separated from unmodified protein
by FPLC gel filtration using a Superose S/12 HR column
(Pharmacia) equilibrated with 0.1 M sodium phosphate
buffer, pH 7.2, and eluted with the same buffer.
Characterisation of PEG-F(ab')2-A5B7-CPG2
Protein content was determined by the bicinchoninic acid
assay (Smith et al., 1985), which is unaffected by the presence
ofPEG. The amount ofPEG attached to F(ab')2-A5B7-CPG2
was determined indirectly by quantitating the residual
number of unmodified amino groups in the derivatised
protein, using trinitrobenzene sulphonic acid according to
the method of Habeeb (1966).
Enzyme assay
CPG2 activity was measured spectrophotometrically in 0.1 M
Tris-HCl buffer, pH 7.3 (final volume 1.0 ml), containing
0.1 mM zinc chloride and 0.06 mM methotrexate (Sigma). The
reaction was initiated by the addition of 10 ,l of protein and
enzyme activity was measured by the decrease in absorbance
at 320 nm. One unit of CPG2 activity corresponds to 1 ,umol
of methotrexate hydrolysed min-' (Sherwood et al., 1985).
Radiolabelling
Aliquots of 1 mg of F(ab')2-A5B7-CPG2 and 1 mg of PEG-
F(ab')2-A5B7-CPG2 were each labelled with 1 mCi of 1251
(Amersham) by the lodogen method (Fraker and Speck,
1978). The specific activities of the 1251-labelled products were
0.65 ,Ci jg-' for F(ab')2-A5B7-CPG2 and 0.54 ,iCi pg-I for
PEG-F(ab')2-A5B7-CPG2. Immunoreactivity of labelled pro-
duct was evaluated by a carcinoembryonic antigen (CEA)
binding assay. Briefly, 8 ng of each labelled product in 100 pl
of phosphate-buffered saline (PBS) was added in sextuplicate
to 96-well vinyl Costar plates previously coated with CEA
(Wagener et al., 1983). After an incubation of 1 h at 37°C,
the wells were washed five times with PBS, and the activity
associated with the wells was counted in a gamma counter
(LKB Wallac). The percentage of radioactivity associated
with CEA was 59.0 + 4.3% for '25I-PEG-F(ab')2-A5B7-
CPG2 and 67.2 + 2.8% for '251-F(ab')2-A5B7-CPG2. Less
than 6% of radioactivity was associated with non-specific
binding for both proteins.
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Biodistribution studies
Inbred MF-I female athymic nude (nu/nu) mice 2-3 months
old were used for all in vivo experiments. For the
biodistribution experiment mice were implanted in the left
flank with c.1 mm3 fragments of the human colon
adenocarcinoma LS174T, and experiments were initiated 2-
3 weeks after implantation when tumours had grown to
approximately 1 cm in diameter. Mice were injected
intravenously with 20 jg of 125I-F(ab')2-A5B7-CPG2 (specific
activity 0.65 ,uCi jig-1) or 20 jg of '25I-PEG-F(ab')2-A5B7-
CPG2 (specific activity 0.54 pCi jg-1). At 1, 6, 24, 48, 72 and
168 h after injection, groups of four mice were sacrificed and
their liver, blood, kidney, lung, spleen, colon and tumour
were excised and weighed. The tissues were dissolved in 7 M
potassium hydroxide and radioactivity was counted in a
gamma counter (LKB Wallac). Counts were corrected for
radioactive decay and results were expressed as the
percentage injected dose of radioactivity per gram of tissue
(% ID g-'). Statistical analysis was performed using a
Student's t-test for unpaired data.
The effect of SB43gal on the biodistribution of I251-PEG-
F(ab')2-A5B7-CPG2
The preparation of SB43gal has been previously reported
(Sharma et al., 1994). Two groups of four athymic nude mice
bearing LS174T human colon carcinoma xenografts were
injected intravenously with 20 jig of 125I-PEG-F(ab')2-A5B7-
CPG2 at time 0. One group of mice was injected
intravenously with SB43gal (50 ,ig per mouse) at 22 h after
receiving conjugate. At 24 h all the mice were sacrificed,
tissues excised and the percentage injected dose per gram of
tissue (%ID g-1) determined.
Results
Purification and characterisation ofPEG-F(ab')2-A5B7-CPG2
Purification of PEG-F(ab')2-A5B7-CPG2 was accomplished
by a single gel filtration step. The superimposed gel filtration
profiles of purified PEG-F(ab')2-A5B7-CPG2 and the
unmodified protein determined separately on a superose S/
12 HR column are shown in Figure 1. The profile for F(ab')2-
A5B7-CPG2 showed two unresolved components (peaks a
and b) which eluted over a region encompassing the elution
volume of globular proteins with molecular weights in the
range 180-250 kDa. From the molecular weights, compo-
nents a and b were estimated to consist of 1 antibody-2
enzyme conjugate and 1 antibody-I enzyme conjugate
respectively. The elution profile of purified PEG-F(ab')2-
A5B7-CPG2 showed displacement of both components
towards higher molecular weights in the range 250-
300 kDa, owing to an increase in molecular size as a result
of coupling to PEG. Determination of free lysine in PEG-
F(ab')2-A5B7-CPG2 showed an average of 23 modified amino
groups out of the available 107. From the rate of
methotrexate turnover, PEG-F(ab')2-A5B7-CPG2 was calcu-
lated to have retained 95.4% of its initial specific enzyme
activity.
Pharmacokinetics
Non-linear regression analyses of the whole blood clearance
of 1251I-PEG-F(ab')2-A5B7-CPG2 and '251I-F(ab')2-A5B7-CPG2
in tumour-bearing mice are shown in Figure 2. 1251-PEG-
F(ab')2-A5B7-CPG2 was removed from the blood much more
slowly and to a lesser extent than '251I-F(ab')2-A5B7-CPG2.
One h after injection 23.74 + 1.42% of the injected dose per
ml (ID ml-1 of 1251-PEG-F(ab')2-A5B7-CPG2 remained in
blood compared with 7.32 + 0.35% ID ml-' of 1251I-F(ab')2-
A5B7-CPG2. By 24 h only 0.19 +0.06% ID ml-1 of 1251.
F(ab')2-A5B7-CPG2 remained in blood compared with
6.28 + 0.37% ID ml-1 of '25I-PEG-F(ab')2-A5B7-CPG2.
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Figure 1 Superimposed gel filtration chromatograms of purified
PEG-F(ab')2-A5B7-CPG2 and F(ab')2-A5B7-CPG2 determined
separately using a Pharmacia superose 12HR 10/12 FPLC
column. The column was equilibrated in 0.1 M sodium
phosphate, pH 7.2, and samples were eluted with the same
buffer at a flow rate of 0.5mlmin-1. Pharmacia gel filtration
standards were used to calibrate the system. ( ), PEG-
F(ab')2-A5B7-CPG2; (--- ), F(ab')2-A5B7-CPG2.
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Figure 2 Clearance of 1251-PEG-F(ab')2-A5B7-CPG2 and 1251_
F(ab')2-A5B7-CPG2 from the blood of nude mice bearing LS174T
xenografts. The results were derived from the blood samples
collected for the biodistribution study and are expressed as a
percentage of the injected dose remaining per ml of blood as a
function of time after injection. Points represent the mean value
for four mice. (-*), '2'I-PEG-F(ab')2-A5B7-CPG2; ( 0),
I21-F(ab')2-A5B7-CPG2.
The percentage of ID ml-1 remaining in blood 168 h after
injection for 125I-F(ab')2-A5B7-CPG2 and 1251-PEG-F(ab')2-
A5B7-CPG2 was 0.013 + 0.003 and 0.083 + 0.038
%ID ml-1 respectively. Half-lives of the terminal elimina-
tion phase t1/2pl) for both proteins were similar, 23.8 h and
25.8 h for 1251I-PEG-F(ab')2-A5B7-CPG2 and 125I-F(ab')2-
A5B7-CPG2 respectively, suggesting the same catabolic rate.
However, 125I-F(ab')2-A5B7-CPG2 always had a significantly
reduced blood level compared with 125I-PEG-F(ab')2-A5B7-
CPG2 at all time points.
Biodistribution study
The biodistributions of 125I-PEG-F(ab')2-A5B7-CPG2 and '25I-
F(ab')2 -A5B7-CPG2 were elevated in tumour-bearing mice
from 1 h to 168 h. The percentage of the injected dose per
gram determined in the tumour and in other organs is shown
in Table I. 1251I-PEG-F(ab')2-A5B7-CPG2 showed significantly
higher tumour uptake than '25I-F(ab')2-CPG2 at all time
points. Peak accumulation of 125I-PEG-F(ab')2-A5B7-CPG2 in
the tumour occurred at 24 h with 6.33 + 0.06% ID g-'
(mean+s.d.), compared with 2.29 + 0.27% ID g-' for 125 J_
F(ab')2-A5B7-CPG2. Normal organ distribution was also
significantly higher for '25I-PEG-F(ab')2-A5B7-CPG2 than
for '25I-F(ab')2-A5B7-CPG2. The % ID g-1 in colon ranged
between 2.13 + 0.43 at 6 h to 0.011 + 0.004 at 168 h for
'25I-PEG-F(ab')2-A5B7-CPG2 and from 0.73 + 0.22 toAntibodies in xenografts with polyethylene glycol
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Table I Tissue localisation of 125I-PEG-F(ab')2-A5B7-CPG2 and 25I-F(ab')2-A5B7-CPG2 in athymic nude mice bearing LSl74T human colon
adenocarcinoma xenografts
Ih 6h
PEG-F(ab')2-A5B7-CPG2 F(ab')2-ASB7-CPG2 PEG-F(ab')2-A5B7-CPG2 F(ab')2-A5B7-CPG2
%ID g-l %ID g1- P %ID g1- %ID g-l P
Blood 37.04±2.21 11.42±0.55 <0.0001 23.6 ± 3.06 6.09±0.78 <0.0001
Liver 7.60 +0.85 4.21 +0.24 <0.001 4.28+0.61 2.72+0.69 <0.05
Kidney 9.16+0.81 4.04±0.79 <0.001 6.02±0.67 2.49± 0.47 <0.001
Lung 9.84±0.61 5.42±0.83 <0.001 7.18+0.21 3.45±0.72 <0.001
Spleen 5.67± 0.52 3.99+ 0.63 <0.02 3.37+ 0.77 1.88± 0.33 <0.05
Colon 1.61 +0.09 0.08+0.04 <0.0001 2.13±0.43 0.73±0.22 <0.005
Tumour 2.55±0.40 1.83±0.41 NSa 5.36± 1.95 1.93±0.67 <0.05
24h 48h
PEG-F(ab')2-ASB7-CPG2 F(ab')2-A5B7-CPG2 PEG-F(ab')2-A5B7-CPG2 F(ab')2-A5B7-CPG2 %IDg-1 %ID g'- P %ID g1- %ID g-l P
Blood 9.79± 0.57 0.94±0.14 <0.0001 4.31 ±0.29 0.33±0.10 <0.001
Liver 1.79±0.25 0.67±0.17 <0.001 1.01±0.07 0.19±0.04 <0.0001
Kidney 2.04±0.30 0.45±0.11 <0.001 1.08±0.04 0.15± 0.04 <0.001
Lung 3.43±0.28 0.68±0.22 <0.0001 1.45±0.17 0.19± 0.07 <0.0001
Spleen 1.58 ±0.22 0.33 ±0.07 <0.0001 0.73 ±0.05 0.11 ±0.02 <0.0001
Colon 0.68±0.17 0.15±0.04 <0.002 0.28±0.01 0.04±0.01 <0.002
Tumour 6.33 ±0.61 2.29±0.27 <0.0001 5.31 ±0.55 1.48±0.37 <0.0001
72h 168h
PEG-F(ab')2-A5B7-CPG2 F(ab')2-A5B7-CPG2 PEG-F(ab')2-A5B7-CPG2 F(ab')2-ASB7-CPG2 %ID g-' %IDg;- P %IDg1- %ID g'- P
Blood 2.45±0.39 0.09±0.01 <0.0001 0.13±0.06 0.02±0.0004 <0.02
Liver 0.55±0.09 0.07±0.01 <0.0001 0.05±0.01 0.02±0.003 <0.005
Kidney 0.60±0.07 0.06±0.01 <0.0001 0.05±0.02 0.02±0.001 <0.05
Lung 0.87±0.11 0.08±0.01 <0.0001 0.05±0.02 0.02±0.003 <0.02
Spleen 0.48 ±0.15 0.05±0.01 <0.005 0.05±0.01 0.01 ±0.003 <0.005
Colon 0.14±0.03 0.020± 0.002 <0.001 0.11 ±0.05 0.005±0.001 NSa
Tumour 3.47±0.49 0.90±0.11 <0.01 1.21±0.16 0.5±0.11 <0.005
Two groups ofathymicnudemicebearing LS174Thumancoloncarcinomaxenograftswereinjectedwith20 Ig of1251_ PEG- F(ab')2-ASB7-CPG2
or 20 jg '25I-PEG-F(ab')2-ASB7-CPG2. At the indicated times fourmice were sacrificed from eachgroup, tissues excisedand the percentageinjected
dose per gram (%ID-'g) was calculated. P-value is the statistical significance ofthe difference observed between the biodistribution of 251-PEG-
F(ab')2-A5B7-CPG2 and 12'I-F(ab')2-ASB7-CPG2 at the time points. aNS, no statistically significant difference. The statistical significance was
evaluatedusing the two-tailed Student's t-test.
0.005 + 0.001 for '211-F(ab')2-A5B7-CPG2. The activity in
liver diminished from 7.66 ± 0.85% ID g-1 at 1 h to
0.05 + 0.01% ID g-1 at 168 h for '25I-PEG-F(ab')2-A5B7-
CPG2 and from 4.21 + 0.24% ID g-' to 0.020 + 0.003%
ID g-1 for '251-F(ab')2-A5B7-CPG2. Differences in uptake in
normal tissue could be accounted for by the differences in
blood clearance. Both conjugates showed increased tumour-
blood ratios over time (Table II). '21J-F(ab')2-A5B7-CPG2 had
the better ratios, ranging from 2.4 at 24 h to 25 at 168 h,
whereas values of 0.65 at 24 h to 9.3 at 168 h were observed
for 125I-PEG-F(ab')2-A5B7-CPG2, indicating a greater specific
accumulation at the tumour site of '251-F(ab')2-A5B7-CPG2.
The effect ofSB43gal
The effect of SB43gal on the biodistribution of 125I-PEG-
F(ab')2-A5B7-CPG2 in nude mice bearing LS174T xenografts is shown in Table III. The %ID g-' of '251-PEG-F(ab')2- A5B7-CPG2 in blood was 10.5-fold lower in mice adminis-
tered with SB43gal than in the untreated group. The
%ID g-' values in other normal tissues were also lower in
the mice administered with SB43gal except colon. This
contrasts with the tumour where administration of SB43gal had no effect on the localisation of 125J-PEG-F(ab')2-A5B7-
CPG2. Tumour-organ ratios were higher in mice adminis-
tered with Sb43gal, except for liver, kidney and colon where
the ratios remained the same. For lung and spleen, tumour-
organ ratio increased 2-fold and for blood the ratio increased
7-fold in the treated mice.
Table II Tumour-organ ratios of '25I-PEG-F(ab')2-ASB7-CPG2
and 1251-F(ab')2-A5B7-CPG2 in athymic nude mice bearing LS174T
human colon adenocarcinoma xenografts
Ih 6h 24h 48h 72h 168h
Tumour to organ ratios of PEG-F(ab')2-ASB7-CPG2
Blood 0.07 0.23 0.65 1.23 1.40 9.31
Liver 0.33 1.25 3.54 5.26 6.31 24.2
Kidney 0.28 0.89 3.10 4.92 5.78 24.2
Lung 0.26 0.75 1.84 3.66 4.00 24.2
Spleen 0.45 1.59 4.01 7.27 7.23 24.2
Colon 1.58 2.52 9.31 18.96 24.78 110.0
Tumour to organ ratios of F(ab')2-A5B7-CPG2
Blood 0.16 0.32 2.44 4.48 10.00 25
Liver 0.43 0.71 3.42 7.79 12.80 25
kidney 0.45 0.77 5.09 9.87 15.00 25
Lung 0.34 0.56 3.37 7.79 11.25 25
Spleen 0.46 1.03 6.94 13.45 18.00 50
Colon 2.29 2.26 15.27 37.00 45.00 100
Tumour-organ ratios were determined by dividing the %ID g-'of
tumour by the %IDg-'oforgan.
Discussion
The distribution in vivo of a parenterally administered
exogenous protein in nude mice bearing the LS174T human
colonic cancer will be affected by its size, charge, rate ofAntibodies in xenografts modified with polyethylene glycol
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Table III Effect of Sb43gal on the clearance and biodistribution of 1251-PEG-F(ab')2A5B7-CPG2 in athymic nude mice bearing
LS174T human colon xenografts
25I-PEG-F(ab)2-A5B7-CPG2 + SB43gal '25I-PEG-F(ab')2- A5B7-CPG2
%ID g-l T/O %ID g'- T/O P
Blood 0.85+0.13 10.5 8.89+0.72 0.7 <0.0001
Liver 1.28+0.49 4.8 1.81±0.39 3.5 <0.005
Kidney 0.87+0.34 7.0 1.38±0.11 4.6 <0.0001
Lung 0.98±0.36 7.0 2.59± 0.56 2.4 <0.0001
Spleen 0.58+0.23 6.2 1.38+0.15 4.6 <0.02
Colon 0.46+0.24 13.5 0.42±0.11 15 <0.05
Tumour 6.10+0.73 6.32+ 0.35 NSa
Two groups offour athymic nudemice bearing LS174Thumancoloncarcinoma xenografts wereinjectedintravenouslywith 20 jg
of1251I-PEG-F(ab')2-A5B7-CPG2 at time 0, and onegroup ofmicewasinjected intravenouslywith SB43gal (50 igpermouse) at 22 h
after receiving conjugate. At 24 h all the mice were sacrificed from each group, tissues excised and the percentage injected doseper gram (%IDg'l)wascalculated. Tumour-organ ratios (T/O)weredetermined bydividingthe %ID g- oftumourby the %ID g of
organ. P-value isthestatistical significance ofthedifference observedinthebiodistribution of'25I-PEG-F(ab')2-A5B7-CPG2 withand
without clearance with SB43gal. aNS, no statistically significant difference. The statistical significance was evaluated using the two-
tailed Student's t-test.
extravasation, rate of drainage into the lymphatic system and
any uptake via specific receptors. The covalent linkage of
PEG-5000 to F(ab')2-A5B7-CPG2 increases its molecular size
significantly from 180-250 kDa to an effective molecular size
of 250-300 kDa. Modification of the conjugate is accom-
panied by a minor loss of enzymatic activity. At the early
(1 h) time point, there is no evidence of exclusion of
pegylated materials from normal tissues, arguing that the
complexes are not in a sized range for which postulated
differences in fenestration between capillaries in tumour or
normal tissues would play a predominant part in the
distribution (Sung et al., 1990).
Our study shows specific tumour localisation of PEG-
F(ab')2-A5B7-CPG2. Tumour uptake peaked at 24 h
(6.33 + 0.61% ID g-1). The specificity of retention was
further demonstrated by the increasing ratios ofPEG-F(ab')2-
A5B7-CPG2 in the tumour compared with normal tissues
with time (Table II). Even though from 1 h to 72 h, tumour-
organ ratios were higher with F(ab')2-A5B7-CPG2 than with
pegylated material by 168 h the ratios were the same for both
proteins in all organs. Blood levels were the exception.
Throughout the experiment tumour-blood ratios were lower
with PEG-F(ab')2-A5B7-CPG2 than with the native con-
jugate. However at all time points, absolute levels of
localisation at the tumour were approximately 3-fold greater
for the former.
Non-linear regression analyses of the whole blood
clearance curves of PEG-F(ab')2-A5B7-CPG2 and F(ab')2-
A5B7-CPG2 demonstrated the persistence of PEG-F(ab')2-
A5B7-CPG2 in blood (Figure 1). F(ab')2-A5B7-CPG2 and
PEG-F(ab')2-A5B7-CPG2 have similar terminal elimination
rates, 25.8 h and 23.8 h respectively. The major difference
between the two blood clearance curves is the significantly
lower levels of F(ab')2-A5B7-CPG2 in the blood compared
with PEG-F(ab')2-A5B7-CPG2 at all time points. At first
sight, it might seem that this reflects a faster and more
extensive extravascular diffusion of F(ab')2-A5B7-CPG2
compared with PEG-F(ab')2-A5B7-CPG2. However, the
biodistribution of both materials in all tissue (Table I), even
at early time points, shows that there is substantially more
pegylated material in the tissues. This suggests that the
component that has changed is the uptake into parenchymal
cells of the liver, driven by carboxypeptidase G2 recognition
(Melton et al., 1987), producing rapid elimination of the 1251
label and/or fragments of protein. It is also conceivable that
the initial rapid decline in blood level of F(ab')2-A5B7-CPG2
may have resulted from the selective removal of a unique
fraction of the native conjugate that could occur if the
injected compound were heterogeneous. We have confirmed
that chemical coupling of the two components produces a
product heterogeneous with respect to size (1:1 antibody-
enzyme and 1:2 antibody-enzyme) and charge (Melton et al.,
1993). Pegylation may mask the inherent differences between
clearance rates of these two types of molecule.
What can be clearly stated, is that the proportion of
injected conjugate retained at the tumour has been
augmented by pegylation. This may be due to the extended
circulatory life, reduction of natural clearance or, possibly,
changes improving convection in the tumour owing to
enhanced hydrophilicity. The saturation of available antigen
at the tumour site is unlikely to be a limiting factor in present
models (Sung et al., 1990). Pegylation appears to have
facilitated egress of the conjugate molecules from the
circulation into both tumour and normal tissues, which
argues a serum concentration-dependent mechanism or
altered physical characteristics or both, but does not suggest
a transfer particular to tumour-associated capillaries. By
inspection (Table I) the rate of loss of pegylated conjugate
from the tumour is less markedly affected than its ingress, if
allowance is made for the increased peak concentration.
The first requirement of improved localisation of
conjugate at the tumour has been met by pegylation, but at
the expense of a greater unwanted concentration of enzyme
in blood and other tissues. To reduce the levels of circulating
conjugate, SB43gal was administered 22 h after injection of
the pegylated conjugate, when maximal tumour localisation
had occurred and sufficient time was allowed for SB43gal-
PEG-F(ab')2-A5B7-CPG2 complexes to clear from the plasma
via the carbohydrate specific receptors in the liver. Previous
work (Sharma et al., 1994; Rogers et al., 1995) suggests that
the initial peak of active enzyme in the liver owing to
accelerated clearance from the circulation has declined by 1 h
after SB43gal administration. The effect of SB43gal on the
biodistribution of PEG-F(ab')2-A5B7-CPG2 is to accelerate
its clearance from the circulation thereby reducing levels of
the conjugate in plasma and extracellular fluid. However, in
the tumour the absolute degree of localisation was not
affected by accelerated clearance, giving rise to a 7-fold
increase in tumour-blood ratio. It is essential that blood
enzyme activity is reduced after tumour localisation has
occurred to avoid prodrug activation in plasma leading to
toxic effects (Bagshawe et al., 1994). Ideally, a balance has to
be struck to remove the non-antigen-bound conjugate as
rapidly and completely as possible from the host after
maximal retention levels have been achieved at the tumour
site. This approach has been modelled successfully for
unmodified conjugate by subsequent administration of
SB43gal (Sharma et al., 1994), and we have now demon-
strated that when the same approach is applied to the
pegylated conjugate, enhanced tumour retention owing to
pegylation is sustained while unbound conjugate can still be
cleared rapidly.
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